PE20121050A1 - Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog - Google Patents

Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog

Info

Publication number
PE20121050A1
PE20121050A1 PE2011002119A PE2011002119A PE20121050A1 PE 20121050 A1 PE20121050 A1 PE 20121050A1 PE 2011002119 A PE2011002119 A PE 2011002119A PE 2011002119 A PE2011002119 A PE 2011002119A PE 20121050 A1 PE20121050 A1 PE 20121050A1
Authority
PE
Peru
Prior art keywords
ftalazin
hedgehog
piperidin
trajectory
pyrazole
Prior art date
Application number
PE2011002119A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Bharvin Kumar Patel
Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20121050A1 publication Critical patent/PE20121050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 ES H O METILO; R2 ES H O METILO; R3, R4, R5, R6 O R7 SON INDEPENDIENTEMENTE H, HALOGENO, CIANO, TRIFLUOROMETILO, METILSULFONIO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-FLUORO-N-METIL-N-(1-(4-(1-METIL-1H-PIRAZOL-5-IL)FTALAZIN-1-IL)PIPERIDIN-4-IL)-2-(TRIFLUOROMETIL)BENZAMIDA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN ANTAGONISTA DE LA TRAYECTORIA DE HEDGEHOG UTIL EN EL TRATAMIENTO DEL CANCER
PE2011002119A 2009-06-19 2010-06-15 Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog PE20121050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
PE20121050A1 true PE20121050A1 (es) 2012-08-09

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002119A PE20121050A1 (es) 2009-06-19 2010-06-15 Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog

Country Status (36)

Country Link
US (2) US8273742B2 (es)
EP (1) EP2443104B1 (es)
JP (1) JP5596139B2 (es)
KR (1) KR101389165B1 (es)
CN (1) CN102459233B (es)
AR (1) AR077014A1 (es)
AU (1) AU2010260244B2 (es)
BR (1) BRPI1011601A2 (es)
CA (1) CA2764542C (es)
CL (1) CL2011003147A1 (es)
CO (1) CO6480932A2 (es)
CR (1) CR20110658A (es)
DK (1) DK2443104T3 (es)
DO (1) DOP2011000386A (es)
EA (1) EA019059B1 (es)
EC (1) ECSP11011541A (es)
ES (1) ES2409054T3 (es)
HK (1) HK1164872A1 (es)
HN (1) HN2011003139A (es)
HR (1) HRP20130408T1 (es)
IL (1) IL216599A (es)
JO (1) JO2931B1 (es)
MA (1) MA33363B1 (es)
MX (1) MX2011014029A (es)
MY (1) MY156667A (es)
NZ (1) NZ596882A (es)
PE (1) PE20121050A1 (es)
PL (1) PL2443104T3 (es)
PT (1) PT2443104E (es)
SG (1) SG177289A1 (es)
SI (1) SI2443104T1 (es)
TN (1) TN2011000627A1 (es)
TW (1) TWI385165B (es)
UA (1) UA106755C2 (es)
WO (1) WO2010147917A1 (es)
ZA (1) ZA201108587B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
JP2012507535A (ja) * 2008-11-03 2012-03-29 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
KR101335770B1 (ko) * 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
MX2017015681A (es) 2015-06-04 2018-09-11 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
WO2016196879A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
KR20230107568A (ko) * 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (es) 1977-06-03 1981-03-07 Pfizer
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
BR0211513A (pt) * 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
EP1496905B1 (en) * 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
KR20150090263A (ko) 2004-09-02 2015-08-05 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
BRPI0820856A2 (pt) * 2007-12-13 2019-05-14 Siena Bhiotech.S.P.A. anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2321298B1 (en) * 2008-08-04 2013-10-02 Amgen Inc. Aurora kinase modulators and methods of use
JP2012507535A (ja) 2008-11-03 2012-03-29 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
KR101335770B1 (ko) 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
DOP2011000386A (es) 2012-02-29
HK1164872A1 (en) 2012-09-28
AR077014A1 (es) 2011-07-27
EP2443104B1 (en) 2013-04-17
PL2443104T3 (pl) 2013-08-30
US20120316174A1 (en) 2012-12-13
US20100324048A1 (en) 2010-12-23
ES2409054T3 (es) 2013-06-24
CO6480932A2 (es) 2012-07-16
JP5596139B2 (ja) 2014-09-24
EP2443104A1 (en) 2012-04-25
TW201113268A (en) 2011-04-16
MX2011014029A (es) 2012-02-21
PT2443104E (pt) 2013-05-07
CA2764542C (en) 2013-09-10
UA106755C2 (uk) 2014-10-10
KR20120024783A (ko) 2012-03-14
AU2010260244B2 (en) 2013-09-05
CN102459233B (zh) 2014-07-02
HRP20130408T1 (en) 2013-06-30
BRPI1011601A2 (pt) 2016-03-22
US8273742B2 (en) 2012-09-25
MA33363B1 (fr) 2012-06-01
SG177289A1 (en) 2012-02-28
SI2443104T1 (sl) 2013-07-31
TWI385165B (zh) 2013-02-11
AU2010260244A1 (en) 2012-01-19
CN102459233A (zh) 2012-05-16
HN2011003139A (es) 2013-07-29
KR101389165B1 (ko) 2014-04-24
JO2931B1 (en) 2015-09-15
IL216599A (en) 2015-09-24
JP2012530705A (ja) 2012-12-06
WO2010147917A1 (en) 2010-12-23
EA201270049A1 (ru) 2012-05-30
TN2011000627A1 (en) 2013-05-24
ECSP11011541A (es) 2012-01-31
NZ596882A (en) 2013-08-30
MY156667A (en) 2016-03-15
CL2011003147A1 (es) 2012-07-20
EA019059B1 (ru) 2013-12-30
IL216599A0 (en) 2012-03-01
ZA201108587B (en) 2013-05-29
US9000023B2 (en) 2015-04-07
DK2443104T3 (da) 2013-05-06
CA2764542A1 (en) 2010-12-23
CR20110658A (es) 2012-02-20

Similar Documents

Publication Publication Date Title
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20140934A1 (es) Derivados de pirazol
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20130215A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3
PE20141375A1 (es) Activadores de glucoquinasa
PE20211700A1 (es) Compuesto heterociclico y su uso
PE20120650A1 (es) Acetamidas sustituidas por n-(hetero)-arilo y 2-(hetero)-arilo, como moduladores de la senalizacion de wnt
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
PE20090839A1 (es) Derivados de isoxazol-imidazol
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
ATE483707T1 (de) 2-cyclopropylthiazolderivate
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20181015A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
BRPI0810402A2 (pt) Derivados de pirrolidina como antagonistas duais dos receptores nk1/nk3
UY29184A1 (es) Derivados de sulfonilbencimidazol
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20070016A1 (es) Compuestos heterociclicos n-enlazados como antagonistas del receptor p2y1
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.

Legal Events

Date Code Title Description
FG Grant, registration